Dave Guebert joins Advitech's Board of Directors

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TSX VENTURE EXCHANGE: AVI

QUEBEC CITY, Sept. 8 /CNW/ - Advitech Inc. (TSX-V: AVI) ("Advitech") is pleased to announce that Mr. David D. Guebert, CA, CPA has been appointed to its Board of Directors. Mr. Guebert replaces Mr. Pierre Labbé, CA, who is leaving the Board of Directors of Advitech after serving for more than three years. Mr. Guebert will also sit on the Audit Committee of Advitech and act as its Chairman.

Mr. Guebert is a Chartered Accountant and a Certified Public Accountant with 30 years of experience in finance and accounting and over 20 years' experience as Chief Financial Officer of public and private companies in the energy and technology sectors. Mr. Guebert is currently the Vice President, Finance and Chief Financial Officer of Primary Corp., a diversified venture capital and merchant banking firm focused on the small cap market and of Cell-Loc Location Technologies Inc., an intellectual property company that has a proprietary technology designed for deployment of wireless data transmission and location based services.

"We are pleased to welcome Mr. Guebert to Advitech's Board," said Mr. Aki Georgacacos, Chairman of the Board of Directors of Advitech. "Mr. Guebert's impressive track record as a seasoned executive of public and private companies will be a significant asset as we look forward to his valuable guidance in financial reporting, management and business matters. On behalf of the Board, I would like to thank Mr. Labbé for his dedication and contribution to Advitech over the past years."

About Advitech

Advitech, which includes its subsidiary Botaneco Specialty Ingredients Inc. since November 20, 2009, is a health sciences and technology company developing, manufacturing and marketing proprietary natural ingredients and formulations for oral and topical applications that have been clinically proven to be safe and effective for improving skin health and well being. The Corporation's products are based on three technological platforms which are: i) a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, ii) XP-828L for immune mediated inflammatory disorders, and iii) IM for anti-aging and wound healing. Advitech produces Hydresia(TM), a natural plant derived specialty ingredient which offers immediate moisturization advantages, formulating cost savings and excellent product aesthetics in a variety of product applications, Dermylex(R) for the treatment of mild-to-moderate psoriasis, and Nudremyl(TM) which acts on skin reconstruction, cellular regeneration and skin structure. More information is available and can be accessed at www.advitech.com and www.botaneco.ca.

This press release contains forward-looking statements, which reflect Advitech's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

%SEDAR: 00021006E

For further information: Michael Stangel, President and CEO, Advitech Inc., 418-948-4084, 215-604-0631, [email protected]